rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMUX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      H.C. Wainwright reiterates Buy on Immunic stock, $22 target
      15h agoInvesting.comIMUX
      Immunic shares fall 5% on third quarter earnings miss
      Nov 13Investing.comIMUX
      Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
      Nov 6Yahoo FinanceIMUX
      Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development - Slideshow
      Nov 5Seeking AlphaIMUX
      Immunic to Participate in Investor Conferences in November

      Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November:

      Nov 2Yahoo FinanceIMUX
      Immunic to host R&D Day on progressive multiple sclerosis

      Immunic Inc (NASDAQ:IMUX, FRA:10VA) will host a virtual Research and Development Day focused on progressive multiple sclerosis (MS) on November 5, the late-stage biotechnology company said on Thursday. The event will outline the company’s plans to initiate a Phase 3 trial of its lead...

      Oct 29Yahoo FinanceIMUX
      Immunic, Inc. (IMUX) Presents at 10th Joint ACTRIMS-ECTRIMS Meeting - MSToronto2026 - Slideshow
      Oct 27Seeking AlphaIMUX
      Immunic presents data on vidofludimus calcium at MS conference
      Oct 21Investing.comIMUX
      Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
      Oct 21MorningstarIMUX
      Immunic adds new Chief People Officer ahead of Phase 3 readout

      Immunic Inc (NASDAQ:IMUX, FRA:10VA) has appointed Jaa Roberson as its first Chief People Officer, adding a senior human resources leader as the biotechnology company prepares for a pivotal multiple sclerosis trial readout expected by the end of 2026. Roberson will report to CEO Erik Lundgren...

      Oct 19Yahoo FinanceIMUX
      Immunic to present vidofludimus calcium data at MS conference
      Oct 7Investing.comIMUX
      Immunic to present four vidofludimus calcium abstracts at MSToronto2026
      Oct 7Yahoo FinanceIMUX
      Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
      Oct 7MorningstarIMUX
      Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics
      Sep 20BarchartIMUX
      Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10
      Sep 17Seeking AlphaIMUX
      Immunic announces resignation of director Duane Nash and board size reduction
      Sep 11Investing.comIMUX
      Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and UnitedHealth (UNH)

      Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailIMUXUNH
      Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10
      Sep 10Seeking AlphaIMUX
      Stifel reiterates Immunic stock rating on MS drug potential
      Sep 10Investing.comIMUX
      H.C. Wainwright reiterates Immunic stock rating on MS drug progress
      Sep 10Investing.comIMUX
      Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis - Slideshow (NASDAQ:IMUX) 2026-09-09
      Sep 9Seeking AlphaIMUX
      Immunic to host virtual relapsing MS R&D Day on September 9

      Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will...

      Sep 2Yahoo FinanceIMUX
      Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

      Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

      Sep 2The Globe and MailIMUXINCYLLY
      Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

      Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.

      Sep 2Yahoo FinanceIMUX
      Immunic appoints Chitrang Davé as chief data and digital officer

      Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it has appointed Chitrang Davé as chief data and digital officer, effective August 30, creating a new executive role focused on data, analytics, artificial intelligence and digital strategy. Davé will report to CEO Erik Lundgren and join...

      Sep 1Yahoo FinanceIMUX
      Roth Capital Partners Adjusts Price Target on Immunic to $29 From $19, Maintains Buy Rating

      Immunic (IMUX) has an average rating of buy and mean price target of $43.09, according to analysts p

      Sep 1Yahoo FinanceTESTIMUX
      Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX)
      Aug 25Seeking AlphaIMUX

      This is the newest page. Registered accounts read further back.